Canada - English - Health Canada

mylan pharmaceuticals ulc - gemcitabine (gemcitabine hydrochloride) - powder for solution - 200mg - gemcitabine (gemcitabine hydrochloride) 200mg - antineoplastic agents

Canada - English - Health Canada

mylan pharmaceuticals ulc - gemcitabine (gemcitabine hydrochloride) - powder for solution - 1g - gemcitabine (gemcitabine hydrochloride) 1g - antineoplastic agents

Canada - English - Health Canada

mylan pharmaceuticals ulc - gemcitabine (gemcitabine hydrochloride) - powder for solution - 2g - gemcitabine (gemcitabine hydrochloride) 2g - antineoplastic agents

Canada - English - Health Canada

accord healthcare inc - gemcitabine (gemcitabine hydrochloride) - solution - 100mg - gemcitabine (gemcitabine hydrochloride) 100mg - antineoplastic agents

Canada - English - Health Canada

apotex inc - gemcitabine (gemcitabine hydrochloride) - solution - 38mg - gemcitabine (gemcitabine hydrochloride) 38mg - antineoplastic agents

Israel - English - Ministry of Health

novartis israel ltd - gemcitabine as hydrochloride - concentrate for solution for infusion - gemcitabine as hydrochloride 40 mg / 1 ml - gemcitabine - gemcitabine - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreatic cancer. gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. breast cancer: gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ovarian cancer: gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.

Canada - English - Health Canada

accord healthcare inc - gemcitabine (gemcitabine hydrochloride) - powder for solution - 1g - gemcitabine (gemcitabine hydrochloride) 1g - antineoplastic agents

Canada - English - Health Canada

accord healthcare inc - gemcitabine (gemcitabine hydrochloride) - powder for solution - 2g - gemcitabine (gemcitabine hydrochloride) 2g - antineoplastic agents

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - gemcitabine hydrochloride, quantity: 1138.526 mg (equivalent: gemcitabine, qty 1000 mg) - injection, concentrated - excipient ingredients: sodium acetate; hydrochloric acid; sodium hydroxide; water for injections - treatment of patients with locally advanced or metastatic non-small celll lung cancer. treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. treatment of patients with 5-fu refractory pancreatic cancer. treatment of patients with bladder cancer, alone or in combination with cisplatin. treatment, in combinatin with paclitaxel, of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. treatment, in combinatin with carboplatin, of patients with recurrent epithelial ovarian carcinoma, who have relapsed > six months following platinum based therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - gemcitabine hydrochloride, quantity: 227.705 mg (equivalent: gemcitabine, qty 200 mg) - injection, concentrated - excipient ingredients: sodium acetate; hydrochloric acid; sodium hydroxide; water for injections - treatment of patients with locally advanced or metastatic non-small celll lung cancer. treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. treatment of patients with 5-fu refractory pancreatic cancer. treatment of patients with bladder cancer, alone or in combination with cisplatin. treatment, in combinatin with paclitaxel, of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. treatment, in combinatin with carboplatin, of patients with recurrent epithelial ovarian carcinoma, who have relapsed > six months following platinum based therapy.